Capital Fund Management (CFM)’s Harmony Biosciences HRMY Stock Holding History

Capital Fund Management (CFM)’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Sell	34,164 -58,364	-63%	-$1.84M	0.01%	1622
2026 Q1	$2.59M	Buy	92,528 +14,510	+19%	+$476K	0.01%	1229
2025 Q4	$2.92M	Buy	78,018 +28,104	+56%	+$924K	0.01%	1499
2025 Q3	$1.38M	Buy	49,914 +13,767	+38%	+$474K	﹤0.01%	1949
2025 Q2	$1.14M	Buy	+36,147	New	+$1.16M	﹤0.01%	1953
2023 Q2	–	Sell	-10,066	Closed	-$329K	–	1767
2023 Q1	$329K	Sell	10,066 -410	-4%	-$18.7K	﹤0.01%	1493
2022 Q4	$577K	Buy	+10,476	New	+$576K	﹤0.01%	1246

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Fund Management (CFM)'s HRMY Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Harmony Biosciences (HRMY) stake by 63% in Q2 2026, selling an estimated $1.84M and leaving 34,164 shares worth $1.24M. The position accounts for 0.01% of the portfolio, ranked #1622.

Capital Fund Management (CFM) first reported a position in HRMY in Q4 2022 and has held it in 7 quarters since. The position peaked at $2.92M in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Capital Fund Management (CFM) held 34,164 shares of Harmony Biosciences worth $1.24M as of Q2 2026.
Capital Fund Management (CFM) sold 58,364 Harmony Biosciences shares in Q2 2026, an estimated $1.84M.
Harmony Biosciences made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1622 holding.
Capital Fund Management (CFM) first reported a position in Harmony Biosciences in Q4 2022 and has held it in 7 quarters since.
Capital Fund Management (CFM)'s Harmony Biosciences position peaked at $2.92M in Q4 2025.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.